Week Ending December 13, 2021

New lung cancer report finds large disparities in prevention, treatment among races and ethnic groups
“While the national lung cancer survival rate has been raised significantly over the past five years, it still remains considerably lower for communities of color.”

First-Line Tiragolumab Plus Atezolizumab Yields Survival Benefit in PD-L1–Positive Metastatic NSCLC
“The anti-TIGIT therapy tiragolumab administered in combination with atezolizumab showed clinically meaningful improvement at the 2.5-year follow-up vs atezolizumab alone for patients with PD-L1–positive metastatic non–small cell lung cancer.”

Alectinib Yields Better Overall Survival Than Ceritinib in ALK-Positive Non–Small Cell Lung Cancer
“A longer overall survival (OS) was achieved in patients with ALK-positive non–small cell lung cancer who were treated with alectinib (Alecensa) compared with ceritinib (Zykadia), according to results from a study published in JAMA Network Open.”

Phase 3 Study of First-Line Serplulimab/Chemotherapy Meets Primary End Point in ES-SCLC
“Treatment with serplulimab yielded a significant improvement in overall survival in combination with chemotherapy in patients with previously untreated extensive-stage small cell lung cancer.”

Talk between immune cells could lead to new cancer vaccine
“In the past decade, immunotherapy has helped save the lives of many cancer patients, many with lung cancer, who might have otherwise faced almost certain death sentences. However, only about 20% of patients who received immune therapies, designed to enhance or override natural limitations on immune system response — saw sustained benefits from treatment.”

NSCLC Therapy is Increasingly Targeted
“Drugs in development and newly approved drugs for non-small cell lung cancer are based on research that has identified driver mutations leading to runaway cell growth and division that characterize cancer.”

VIDEOS:
Former US Football Player Presses for Cancer Cure in Honor of Late Wife
“Lung cancer is the deadliest form of the disease, according to the American Cancer Society. But it doesn’t get nearly the same amount of research dollars as breast or prostate cancer. That may be changing, thanks to one man’s efforts and new guidelines from the Centers for Disease Control and Prevention, or CDC. VOA’s Saba Shah Khan reports.”

New Hope for Deadly Lung Cancer Diagnosis
“Rahul P. Bhandari, M.D. is a Radiation Oncologist at Tampa Bay Radiation Oncology joins Gayle Guyardo the host of the nationally syndicated health and wellness show Bloom about celebrities diagnosed with lung cancer and survived.”

Dr. Bestvina on Challenges With Interpreting Molecular Reports in Lung Cancer
“Christine Bestvina, MD, assistant professor of medicine, Section of Hematology/Oncology, Department of Medicine, University of Chicago Medicine, discusses challenges with interpreting molecular reports in lung cancer.”